Abstract 84P
Background
Tumor-specific neoantigens arising from non-synonymous mutations have become increasingly attractive targets for immunotherapies. The accurate identification and prioritization of neoantigens is crucial to design personalized therapies for each cancer patient. Putative immunogenic neoantigens are currently selected by using several peptide-HLA-I binding predictors. While HLA-I binding affinity is essential to tumor cell presentation of neoantigens, it is insufficient to determine neoantigen immunogenicity. As such, the vast majority of predicted tumor neoantigens (98%) are not immunogenic and ineffective in activating antitumor responses. To address this challenge, we propose integrating T-cell receptor (TCR) repertoire profiles of tumor infiltrating lymphocytes (TILs), a key determinant of immunogenicity, in the current neoantigen prediction workflow.
Methods
We sequenced the CDR3 regions of TCR beta chain (TCRB) repertoire in 27 colorectal cancer (CRC) patients and predicted neopeptide-TCR binding by using our previously published predictor, epiTCR and another existing tool pMTNet. We constructed a machine learning model which considers both peptide-HLA-I and peptide-TCR binding features to prioritize high quality immunogenic neoantigen candidates. We further performed ELISpot assay on autologous PBMCs from four CRC patients to experimentally validate the effectiveness of our model. Finally, we selected the highest immunogenic candidate to perform 10X single-cell sequencing to identify the potential neoantigen-specific TCRs for cell-based vaccine development.
Results
We showed that 5.5% of neopeptide candidates despite having weak HLA-I binding affinity are capable of binding to TCR at predicted rank < 2%. The integrated model achieved higher accuracy for ranking immunogenic neopeptides than the conventional NetMHCpan tool solely relying on peptide-HLA-I binding features.
Conclusions
Our study presents an efficient process to select and prioritize neoantigens exhibiting both HLA presentation and immunogenicity for personalized cancer immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Genetics Institute.
Funding
Nexcalibur Therapeutics.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
485P - LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers
Presenter: Sai-Hong Ou
Session: Poster Display
Resources:
Abstract
486P - Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong’s healthcare system
Presenter: Herbert Ho Fung Loong
Session: Poster Display
Resources:
Abstract
487P - Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patients
Presenter: Jian Wei Tan
Session: Poster Display
Resources:
Abstract
488P - Pulmonary ground glass opacity lesions: Immune ecosystem and its clinical relevances of early-stage lung adenocarcinoma
Presenter: Shensi Shen
Session: Poster Display
Resources:
Abstract
489TiP - BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
Presenter: Wentao Yu
Session: Poster Display
Resources:
Abstract
491P - Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
Presenter: Ziheng Wu
Session: Poster Display
Resources:
Abstract
492P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display
Resources:
Abstract
493P - The prognostic value of 4L lymph node dissection in left-sided operable non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Lei Peng
Session: Poster Display
Resources:
Abstract
495P - Intrinsic STING of CD8+T cells regulates self-metabolic reprogramming and exerts anti-tumor effects
Presenter: Qiuli Xu
Session: Poster Display
Resources:
Abstract
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract